CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive: Given the reduced importance of CXCR4/CXCL12 in CML compared with normal HSCs, and CXCR4 antagonists are potential therapeutics for treatment of CML, the particular application that captures our attention is the recurrence of active leukemia.